Interventional Treatment Room, Hengshui People's Hospital, Hengshui, China.
Pak J Pharm Sci. 2023 Mar;36(2(Special)):653-658.
To evaluate the clinical efficacy and the influence of fibrinogen, homocysteine and prognosis in acute ischemic stroke (AIS) treated with tirofiban plus TERVO stent thrombectomy. A retrospective study was conducted among 82 patients with AIS admitted to the Department of Neurology in Hengshui People's Hospital from December 2018 to December 2020 and they were evenly divided into control group and study group according to different methods. The control group received TERVO stent thrombectomy; the study group received tirofiban plus. The clinical efficacy, modified thrombolysis in cerebral infarction (mTICI) grade, serum levels of fibrinogen and homocysteine, National Institute of Health stroke scale (NIHSS), and activity of daily living (ADL) scores were compared. Significant higher clinical efficacy was observed in the study group vs. control group (all p<0.05). The study group witnessed lower percentage of 0~1 grade of mTICI blood flow in relative to the control group (all p<0.05). After treatment, significant reduction was observed in FIB and HCY in both groups, but the treatment in the study group resulted in a greater reduction (all p<0.05). After treatment, both groups reported a significant increase in NIHSS score and ADL score, with more increase in the study group (all p<0.05). The safety profiles were similar in the two groups with respect to the adverse reactions (p>0.05). Tirofiban plus TERVO stent thrombectomy could improve vascular recanalization rate, reduce fibrinogen and homocysteine levels and improve short-term prognosis in AIS patients.
评价替罗非班联合 TERVO 支架取栓治疗急性缺血性脑卒中（AIS）的临床疗效及对纤维蛋白原、同型半胱氨酸和预后的影响。选取 2018 年 12 月至 2020 年 12 月衡水市人民医院神经内科收治的 82 例 AIS 患者进行回顾性研究，根据不同方法将患者分为对照组和观察组，各 41 例。对照组患者采用 TERVO 支架取栓治疗，观察组患者采用替罗非班联合治疗。比较两组患者的临床疗效、改良脑梗死溶栓（mTICI）分级、纤维蛋白原和同型半胱氨酸（HCY）血清水平、美国国立卫生研究院卒中量表（NIHSS）评分和日常生活活动（ADL）评分。观察组患者的临床疗效显著高于对照组（均 P<0.05）。观察组患者 mTICI 血流 0~1 级的比例显著低于对照组（均 P<0.05）。治疗后，两组纤维蛋白原（FIB）和 HCY 均显著降低，观察组降低更显著（均 P<0.05）。治疗后，两组 NIHSS 评分和 ADL 评分均显著升高，观察组升高更显著（均 P<0.05）。两组患者不良反应发生率相似（P>0.05）。替罗非班联合 TERVO 支架取栓治疗可提高 AIS 患者血管再通率，降低纤维蛋白原和同型半胱氨酸水平，改善短期预后。
